Huaota：HB0017 has been formally accepted for review.
Pierre Fabre：BRAFTOVI®Encorafenib marketing application submitted
GeneScience：Triptorelin Acetate was approved
CARsgen：Satricabtagene autoleucel approved for marketing in China.
CSPC：SYS6043 is proposed to be granted Breakthrough Therapy designation.
Astellas：PADCEV®Enfortumab vedotinreceived marketing approval
Sino：LM-302 has been formally accepted for review.
Pfizer：Sigvotatug vedotin failed in Phase III.
Haisco: Recently entered into an exclusive license agreement with Nuvectis Pharma, Inc. in the United States.
Takeda：ADZYNMA®Apadamtase alfa marketing application submitted
